Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

ST Humphrey Says Still 'Buy' Allergan

ST Humphrey keeps its buy rating on Allergan (AGN).

Analyst Ken Lauden says Botox's label now has broadened beyond crossed eyes and muscle spasms to include brow furrow and frown lines. He says investors have been waiting for this for some time. He notes Botox is about one-third of the company's sales, which he says should work higher. Lauden expects cosmetic approval, and the subsequent direct-to-consumer campaign, to serve as a springboard for 20% plus revenue growth in late 2002 and 2003. He sees in-line third quarter results. Lauden also says upcoming catalysts include the launch and progress of Botox cosmetic direct-to-consumer campaign and third quarter results.

blog comments powered by Disqus